• Samsung Biologics' subsidiary Samsung Peptide reached a provisional 97.99% stake in PolyPeptide Group with concert parties, totaling 32,458,892 shares.
• By October 30, 2026, shareholders tendered 32,350,302 shares, representing 97.66% of issued capital and voting rights, or 97.98% of shares covered.
• Definitive offer results are expected on November 5, 2026.
• Settlement was postponed pending regulatory approvals, with completion now expected toward the end of 2026 or in the first quarter of 2027.
• Following settlement, Samsung Peptide intends to squeeze out remaining public shareholders and seek delisting from SIX.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PolyPeptide Group AG published the original content used to generate this news brief via EQS News (Ref. ID: adhoc_2426080_en) on November 02, 2026, and is solely responsible for the information contained therein.